

Q6	Write about market exclusivity for New chemical entity, new chemical entity for organ disease, first to file ANDA and for NDA 505(b)	CO3
SECTION B		
1. Each question will carry 10 marks 2. Instruction: Write short / brief notes		
Q 1	Mention any 4 different types of control groups. Explain any two of them.	CO3
Q 2	Discuss important points mentioned in Belmonts report regarding ethics in clinical research.	CO5
Q 3	Write about vulnerable population. Why is the name vulnerable used for them. a. In which phase of clinical trials are geriatric population enrolled. Give all possible cases.	CO1
Q 4	Write some principles of Good Clinical Practices. (At least 6)	CO4
Q 5	Write about special treatment given (or should be given) to a. Pregnant women b. Pediatrics	CO5
Section C		
1. Each Question carries 20 Marks. 2. Instruction: Write long answer.		
Q1	Write about a. ANDA b. NDA 505(b) c. IND d. Orange book <p style="text-align: center;">OR</p> a. Write about life span of a drug including patent protection and market exclusivity given by FDA. b. Mention salient feature of Hatch Waxman Act and the benefits it has for generic and branded products	CO2